SEC 13F Intelligence

Mpm Bioimpact LLC / MLTX

Mpm Bioimpact LLC’s Moonlake Immunotherapeutics Position

Does Mpm Bioimpact LLC own Moonlake Immunotherapeutics (MLTX)? Yes — 1.81M shares worth $34M (+2.61% of its 13F portfolio) as of Q1 2026, up from 313.6K shares the prior filed quarter.

Position Value
$34M
Q1 2026
Shares
1.81M
% of Portfolio
+2.61%
Quarters Held
10
currently held

Position History MLTX

Reported value by quarter
Q2 ’23: $15MQ2 ’23Q3 ’23: $17MQ4 ’23: $18MQ4 ’23Q1 ’24: $15MQ2 ’24: $15MQ2 ’24Q3 ’24: $18MQ4 ’24: $17MQ4 ’24Q1 ’25: $12MQ2 ’25: $15MQ2 ’25Q1 ’26: $34Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q1 20261.81M$34M+2.61%
Q2 2025313.6K$15M+2.56%
Q1 2025316.0K$12M+2.12%
Q4 2024315.2K$17M+2.42%
Q3 2024349.1K$18M+2.64%
Q2 2024343.2K$15M+2.35%
Q1 2024296.1K$15M+2.39%
Q4 2023294.6K$18M+4.16%
Q3 2023294.2K$17M+4.48%
Q2 2023295.1K$15M+3.03%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Mpm Bioimpact LLC’s full portfolio or all institutional holders of MLTX.